Download
s12890-022-02066-z.pdf 736,17KB
WeightNameValue
1000 Titel
  • Stelara struck: a case of noninfectious pneumonitis secondary to ustekinumab
1000 Autor/in
  1. Despotes, Katherine A. |
  2. Vigeland, Christine |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-07-19
1000 Erschienen in
1000 Quellenangabe
  • 22:280
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12890-022-02066-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297594/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: We describe a case of acute hypoxic respiratory failure due to drug induced lung disease secondary to ustekinumab, which is a monoclonal antibody used to treat psoriasis, psoriatic arthritis, and inflammatory bowel disease. CASE PRESENTATION: A 33-year-old man with a history of Crohn’s disease presented with fevers, myalgias, and abdominal pain, and subsequently developed acute hypoxemic respiratory failure approximately 2 weeks after restarting ustekinumab for his Crohn’s disease. Cross-sectional chest imaging showed ground glass opacities and bilateral consolidations. Due to progressive hypoxia, he ultimately required intubation and mechanical ventilation. Broad infectious and autoimmune work up was negative, making drug induced interstitial lung disease (DILD) the leading consideration. He was treated with high dose steroids with dramatic improvement in his respiratory status. At follow up, his imaging findings had largely resolved, and his pulmonary function tests were normal. CONCLUSIONS: For patients presenting with acute hypoxic respiratory failure, it is critical to identify the underlying cause. In addition to testing for common respiratory infections that can cause respiratory failure, patients should also be evaluated for risk factors for developing atypical or opportunistic infections as well as inflammatory pneumonitis. Due to receiving ustekinumab, our patient was both at risk for developing an opportunistic infection as well as DILD. Although rare, DILD is a recognized toxicity of ustekinumab. Ustekinumab can cause significant lung injury, as in our patient, but with steroids and avoidance of future doses of the medication, our patient demonstrated good recovery. Reassuring outcomes have similarly been described in the literature; however, this case provides further details about outcomes with long-term follow-up clinical, imaging, and pulmonary function testing data available. We recommend consideration of high dose steroids for these patients for whom DILD is suspected.
1000 Sacherschließung
lokal ARDS
lokal Drug induced ILD
lokal Ustekinumab
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RGVzcG90ZXMsIEthdGhlcmluZSBBLg==|http://orcid.org/0000-0003-4468-374X
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6438172.rdf
1000 Erstellt am 2022-10-28T10:50:24.755+0200
1000 Erstellt von 329
1000 beschreibt frl:6438172
1000 Bearbeitet von 329
1000 Zuletzt bearbeitet 2022-11-11T18:25:39.280+0100
1000 Objekt bearb. Fri Nov 11 18:25:38 CET 2022
1000 Vgl. frl:6438172
1000 Oai Id
  1. oai:frl.publisso.de:frl:6438172 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source